Evaluation of a pharmacology-driven dosing algorithm of 3-weekly paclitaxel using therapeutic drug monitoring: A pharmacokinetic-pharmacodynamic simulation study

Clinical Pharmacokinetics

Volumn 51, Issue 9, 2012, Pages 607-617

  Joerger, Markus ^a   Kraff, Stefanie ^b   Huitema, Alwin D R ^c   Feiss, Gary ^d   Moritz, Berta ^e   Schellens, Jan H M ^f,g   Beijnen, Jos H ^c,g   Jaehde, Ulrich ^b  

^a CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^b UNIVERSITY OF BONN   (Germany)

^c SLOTERVAART HOSPITAL   (Netherlands)

^d SALADAX BIOMEDICAL INC   (United States)

^e CESAR Central European Society for Anticancer Drug Research EWIV   (Austria)

^f NETHERLANDS CANCER INSTITUTE   (Netherlands)

^g UTRECHT UNIVERSITY   (Netherlands)

Author keywords

algorithm; antineoplastics; Bayesian analysis; drug monitoring; lung cancer; neutropenia; paclitaxel; pharmacokinetic modelling; pharmacokinetic pharmacodynamic relationships; pharmacology; population pharmacokinetics

Indexed keywords

BILIRUBIN; CARBOPLATIN; PACLITAXEL;

ALGORITHM; ARTICLE; BODY SURFACE; BONE MARROW TOXICITY; COMPUTER PROGRAM; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG MONITORING; FEMALE; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NEUTROPHIL COUNT; PRIORITY JOURNAL; SIMULATION;

AGED; ALGORITHMS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; COMPUTER SIMULATION; DRUG MONITORING; HUMANS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; NEOPLASMS; NEUTROPENIA; PACLITAXEL;

EID: 84864750143     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.2165/11634210-000000000-00000     Document Type: Article

References (54)

1. Belani CP, Lee JS, Socinski MA, et al. Randomized phase III trial comparing cisplatin-etoposide to carboplatin-paclitaxel in advanced or metastatic nonsmall cell lung cancer. Ann Oncol 2005; 16 (7): 1069-75 (Pubitemid 41418307)
2. Sparano JA, Wang M, Martino S, et al. Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 2008; 358 (16): 1663-71 (Pubitemid 351549913)
3. Sledge GW, Neuberg D, Bernardo P, et al. Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). J Clin Oncol 2003; 21 (4): 588-92 (Pubitemid 46621890)
4. du Bois A, Luck HJ, Meier W, et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 2003; 95 (17): 1320-9
5. Gianni L, Kearns CM, Giani A, et al. Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. J Clin Oncol 1995; 13 (1): 180-90
6. Ohtsu T, Sasaki Y, Tamura T, et al. Clinical pharmacokinetics and pharmacodynamics of paclitaxel: a 3-hour infusion versus a 24-hour infusion. Clin Cancer Res 1995; 1 (6): 599-606
7. Henningsson A, Sparreboom A, Sandstrom M, et al. Population pharmacokinetic modelling of unbound and total plasma concentrations of paclitaxel in cancer patients. Eur J Cancer 2003; 39 (8): 1105-14 (Pubitemid 36555868)
8. Karlsson MO, Molnar V, Freijs A, et al. Pharmacokinetic models for the saturable distribution of paclitaxel. Drug Metab Dispos 1999; 27 (10): 1220-3 (Pubitemid 29463611)
9. Huizing MT, Vermorken JB, Rosing H, et al. Pharmacokinetics of paclitaxel and three major metabolites in patients with advanced breast carcinoma refractory to anthracycline therapy treated with a 3-hour paclitaxel infusion: a European Cancer Centre (ECC) trial. Ann Oncol 1995; 6 (7): 699-704
10. Joerger M, Huitema AD, Huizing MT, et al. Safety and pharmacology of paclitaxel in patients with impaired liver function: a population pharmacokinetic-pharmacodynamic study. Br J Clin Pharmacol 2007; 64 (5): 622-33 (Pubitemid 47568820)
11. Venook AP, Egorin MJ, Rosner GL, et al. Phase I and pharmacokinetic trial of paclitaxel in patients with hepatic dysfunction: Cancer and Leukemia Group B 9264. J Clin Oncol 1998; 16 (5): 1811-9
12. Henningsson A, Karlsson MO, Vigano L, et al. Mechanism-based pharmacokinetic model for paclitaxel. J Clin Oncol 2001; 19 (20): 4065-73 (Pubitemid 32976694)
13. Huizing MT, Keung AC, Rosing H, et al. Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients. J Clin Oncol 1993; 11 (11): 2127-35 (Pubitemid 23332248)
14. Friberg LE, Henningsson A, Maas H, et al. Model of chemotherapy-induced myelosuppression with parameter consistency across drugs. J Clin Oncol 2002; 20 (24): 4713-21 (Pubitemid 36025290)
15. Jennens R, Rischin D, Yuen K, et al. Comparison of neutropenia in a randomized, crossover trial of 3-, 6-, and 24-h infusions of paclitaxel. Gynecol Oncol 2003; 91 (1): 190-3 (Pubitemid 37188610)
16. Augusto C, Pietro M, Cinzia M, et al. Peripheral neuropathy due to paclitaxel: study of the temporal relationships between the therapeutic schedule and the clinical quantitative score (QST) and comparison with neurophysiological findings. J Neurooncol 2008; 86 (1): 89-99 (Pubitemid 350263438)
17. Blumenschein Jr GR, Khuri FR, von Pawel J, et al. Phase III trial comparing carboplatin, paclitaxel, and bexarotene with carboplatin and paclitaxel in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT II. J Clin Oncol 2008; 26 (11): 1879-85
18. Hensing TA, Peterman AH, Schell MJ, et al. The impact of age on toxicity, response rate, quality of life, and survival in patients with advanced, stage IIIB or IV nonsmall cell lung carcinoma treated with carboplatin and paclitaxel. Cancer 2003; 98 (4): 779-88 (Pubitemid 36959275)
19. Herbst RS, Prager D, Hermann R, et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005; 23 (25): 5892-9
20. Socinski MA, Schell MJ, Peterman A, et al. Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer. J Clin Oncol 2002; 20 (5): 1335-43 (Pubitemid 34182817)
21. Treat JA, Gonin R, Socinski MA, et al. A randomized, phase III multicenter trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin in patients with advanced or metastatic non-smallcell lung cancer. Ann Oncol 2010; 21 (3): 540-7
22. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355 (24): 2542-50 (Pubitemid 44917502)
23. Ramalingam SS, Dahlberg SE, Langer CJ, et al. Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599. J Clin Oncol 2008; 26 (1): 60-5
24. Kubota K, Kawahara M, Ogawara M, et al. Vinorelbine plus gemcitabine followed by docetaxel versus carboplatin plus paclitaxel in patients with advanced non-small-cell lung cancer: a randomised, open-label, phase III study. Lancet Oncol 2008; 9 (12): 1135-42
25. Blay JY, Chauvin F, Le Cesne A, et al. Early lymphopenia after cytotoxic chemotherapy as a risk factor for febrile neutropenia. J Clin Oncol 1996; 14 (2): 636-43 (Pubitemid 26051031)
26. Silber JH, Fridman M, DiPaola RS, et al. First-cycle blood counts and subsequent neutropenia, dose reduction, or delay in early-stage breast cancer therapy. J Clin Oncol 1998; 16 (7): 2392-400 (Pubitemid 28309033)
27. Crawford J, Glaspy JA, Stoller RG, et al. Final results of a placebo-controlled study of filgrastim in small-cell lung cancer: exploration of risk factors for febrile neutropenia. Support Cancer Ther 2005; 3 (1): 36-46
28. Joerger M, Huitema AD, Richel DJ, et al. Population pharmacokinetics and pharmacodynamics of paclitaxel and carboplatin in ovarian cancer patients: a study by the European organization for research and treatment of cancerpharmacology and molecular mechanisms group and new drug development group. Clin Cancer Res 2007; 13 (21): 6410-8 (Pubitemid 350075031)
29. Miller AA, Rosner GL, Egorin MJ, et al. Prospective evaluation of body surface area as a determinant of paclitaxel pharmacokinetics and pharmacodynamics in women with solid tumors: Cancer and Leukemia Group B study 9763. Clin Cancer Res 2004; 10 (24): 8325-31 (Pubitemid 40053393)
30. Mould DR, Fleming GF, Darcy KM, et al. Population analysis of a 24-h paclitaxel infusion in advanced endometrial cancer: a gynaecological oncology group study. Br J Clin Pharmacol 2006; 62 (1): 56-70 (Pubitemid 44195243)
31. Huizing MT, Giaccone G, van Warmerdam LJ, et al. Pharmacokinetics of paclitaxel and carboplatin in a dose-escalating and dose-sequencing study in patients with non-small-cell lung cancer: the European Cancer Centre. J Clin Oncol 1997; 15 (1): 317-29 (Pubitemid 27020590)
32. Jiko M, Yano I, Sato E, et al. Pharmacokinetics and pharmacodynamics of paclitaxel with carboplatin or gemcitabine, and effects of CYP3A5 and MDR1 polymorphisms in patients with urogenital cancers. Int J Clin Oncol 2007; 12 (4): 284-90 (Pubitemid 47262740)
33. Kobayashi M, Oba K, Sakamoto J, et al. Pharmacokinetic study of weekly administration dose of paclitaxel in patients with advanced or recurrent gastric cancer in Japan. Gastric Cancer 2007; 10 (1): 52-7 (Pubitemid 46357474)
34. Mielke S, Sparreboom A, Steinberg SM, et al. Association of paclitaxel pharmacokinetics with the development of peripheral neuropathy in patients with advanced cancer. Clin Cancer Res 2005; 11 (13): 4843-50 (Pubitemid 41557204)
35. Nakajima M, Fujiki Y, Kyo S, et al. Pharmacokinetics of paclitaxel in ovarian cancer patients and genetic polymorphisms of CYP2C8, CYP3A4, and MDR1. J Clin Pharmacol 2005; 45 (6): 674-82 (Pubitemid 40696210)
36. de Jonge ME, van den Bongard HJ, Huitema AD, et al. Bayesian pharmacokinetically guided dosing of paclitaxel in patients with non-small cell lung cancer. Clin Cancer Res 2004; 10 (7): 2237-44 (Pubitemid 38445680)
37. EU Clinical Trials Register. An open-label, randomized, parallel group study of patients treated with paclitaxel with standard dosing versus pharmacokinetic guided dose adjustment in patients with advanced NSCLC. EudraCT number 2010-023688-16 online. Available from URL: https://www. clinicaltrialsregister.eu/ctr-search/trial/2010-023688-16/DE Accessed 2012 Jun 13
38. Joerger M, Huitema AD, van den Bongard DH, et al. Quantitative effect of gender, age, liver function, and body size on the population pharmacokinetics of paclitaxel in patients with solid tumors. Clin Cancer Res 2006; 12 (7 Pt 1): 2150-7
39. Huizing MT, Sparreboom A, Rosing H, et al. Quantification of paclitaxel metabolites in human plasma by high-performance liquid chromatography. J Chromatogr B Biomed Appl 1995; 674 (2): 261-8 (Pubitemid 26005553)
40. Beal S, Sheiner LB, Boeckmann A, et al. NONMEM user's guides 1989-2009. Ellicott City (MD): Icon Development Solutions, 2009
41. Minami H, Sasaki Y, Watanabe T, et al. Pharmacodynamic modeling of the entire time course of leukopenia after a 3-hour infusion of paclitaxel. Jpn J Cancer Res 2001; 92 (2): 231-8 (Pubitemid 32237100)
42. Bulitta JB, Zhao P, Arnold RD, et al. Multiple-pool cell lifespan models for neutropenia to assess the population pharmacodynamics of unbound paclitaxel from two formulations in cancer patients. Cancer Chemother Pharmacol 2009; 63 (6): 1035-48
43. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361 (10): 947-57
44. Ranson M, Davidson N, Nicolson M, et al. Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-smallcell lung cancer. J Natl Cancer Inst 2000; 92 (13): 1074-80 (Pubitemid 30616481)
45. Gomez H, Hidalgo M, Casanova L, et al. Risk factors for treatment-related death in elderly patients with aggressive non-Hodgkin's lymphoma: results of a multivariate analysis. J Clin Oncol 1998; 16 (6): 2065-9 (Pubitemid 28265042)
46. Caggiano V, Stolshek BS, Delgado DJ, et al. First and all cycle febrile neutropenia hospitalizations (FNH) and costs in intermediate grade non-Hodgkins lymphoma (IGL) patients on standard-dose CHOP therapy abstract no. 1810. Blood 2001; 98: 431a
47. Meza L, Baselga J, Holmes FA, et al. Incidence of febrile neutropenia (FN) is directly related to duration of severe neutropenia (DSN) after myelosuppressive chemotherapy abstract no. 2840. Proc Am Soc Clin Oncol 2002; 21: 255b
48. Mayordomo JI, Lopez A, Vinolas N, et al. Retrospective cost analysis of management of febrile neutropenia in cancer patients in Spain. Curr Med Res Opin 2009; 25 (10): 2533-42
49. Woo MH, Relling MV, Sonnichsen DS, et al. Phase I targeted systemic exposure study of paclitaxel in children with refractory acute leukemias. Clin Cancer Res 1999; 5 (3): 543-9 (Pubitemid 29131963)
50. van der Bol JM, Mathijssen RH, Creemers GJ, et al. A CYP3A4 phenotypebased dosing algorithm for individualized treatment of irinotecan. Clin Cancer Res 2010; 16 (2): 736-42
51. Mielke S, Sparreboom A, Behringer D, et al. Paclitaxel pharmacokinetics and response to chemotherapy in patients with advanced cancer treated with a weekly regimen. Anticancer Res 2005; 25 (6C): 4423-7 (Pubitemid 41729490)
52. Gonzalez-Angulo AM, Hortobagyi GN. Optimal schedule of paclitaxel: weekly is better. J Clin Oncol 2008; 26 (10): 1585-7
53. Seidman AD, Berry D, Cirrincione C, et al. Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. J Clin Oncol 2008; 26 (10): 1642-9
54. Belani CP, Ramalingam S, Perry MC, et al. Randomized, phase III study of weekly paclitaxel in combination with carboplatin versus standard every-3-weeks administration of carboplatin and paclitaxel for patients with previously untreated advanced non-small-cell lung cancer. J Clin Oncol 2008; 26 (3): 468-73 (Pubitemid 351171701)